NB.1.8.1: Genomic Insights into a Rapidly Emerging SARS-CoV-2 Omicron Subvariant

Introduction: NB.1.8.1 is a recently identified sublineage of the SARS-CoV-2 Omicron variant, first detected in early 2025. Its rapid emergence across regions has raised concerns due to its distinct genetic makeup and potential public health implications. This review summarizes the genomic features, clinical presentation, epidemiology, and public health concerns of NB.1.8.1, highlighting its divergence from earlier SARS-CoV-2 lineages. Methods: Data were compiled from genomic analyses, epidemiological studies, clinical observations, and comparative reviews of previous variants. Focus was placed on spike and nonspike mutations, immune evasion, and transmission dynamics. Results: NB.1.8.1 stems from the JN.1 lineage and harbors several novel spike mutations enhancing ACE2 binding and transmissibility. Its global prevalence increased from 2.5% to over 10% within four weeks. Clinically, it resembles other Omicron subvariants, causing mild symptoms, such as fever, cough, fatigue, and headache. Neutralization assays show a 1.5–1.6- fold reduction in antibody activity, suggesting partial immune escape but minimal impact on vaccine protection against severe disease. Non-spike mutations also affect replication and immune modulation. Phylogenetic studies indicate recombinant origins, signifying divergence from lineages like Alpha, Beta, Delta, and earlier Omicron variants. Discussion: NB.1.8.1 is a rapidly spreading Omicron subvariant with novel spike mutations enhancing transmissibility and partial immune escape. Despite mild clinical severity, its swift rise and recombinant origins emphasize ongoing viral evolution. Continued surveillance, updated vaccines, and adaptive public health measures are essential to limit the spread and strengthen pandemic preparedness. Conclusions: NB.1.8.1 is a fast-spreading Omicron subvariant with modest immune escape and low clinical severity. Continued genomic surveillance, updated vaccinations, and public health interventions are essential to curb its spread. Understanding its mutation profile and evolutionary path will support future vaccine design and therapeutic strategies.